Propensity score analysis of overall survival between first‐ and second‐generation EGFR‐TKIs using real‐world data

Autor: Kazuhiro Asada, Joe Shindoh, Kazuyoshi Imaizumi, Masato Karayama, Akihito Kubo, Yuko Oya, Kenta Murotani, Eiji Kunii, Takafumi Suda, Sayako Morikawa, Tatsuya Yoshida, Toyoaki Hida, Takeshi Tsuda, Kentaro Ito, Kosuke Takahashi, Teppei Yamagichi, Tomoki Kimura, Shunsaku Hayai, Osamu Hataji, Hirokazu Taniguchi, Takashi Abe, Naoki Inui, Motoyasu Okuno
Rok vydání: 2020
Předmět:
Adult
Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
non–small‐cell lung cancer
Afatinib
Disease-Free Survival
Erlotinib Hydrochloride
03 medical and health sciences
0302 clinical medicine
Gefitinib
Japan
Clinical Research
Carcinoma
Non-Small-Cell Lung
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Clinical endpoint
Humans
Medicine
Osimertinib
Protein Kinase Inhibitors
EGFR‐TKI
Aged
Aged
80 and over
Acrylamides
Aniline Compounds
business.industry
Hazard ratio
General Medicine
Middle Aged
propensity scoring analysis
real‐world data
respiratory tract diseases
ErbB Receptors
Clinical trial
030104 developmental biology
030220 oncology & carcinogenesis
Mutation
Propensity score matching
Female
Original Article
Erlotinib
business
medicine.drug
Zdroj: Cancer Science
ISSN: 1349-7006
1347-9032
DOI: 10.1111/cas.14560
Popis: We constructed a data set of EGFR‐mutant non–small‐cell lung carcinoma (NSCLC) patients, and compared the overall survival of first‐generation (1G), and second‐generation (2G) EGFR‐tyrosine kinase inhibitors (TKIs) in clinical practice using a propensity score. We reviewed the clinical data of consecutive EGFR‐mutated NSCLC patients who received EGFR‐TKI therapy between January 2008 and August 2017 at 11 institutions in Japan. The primary endpoint was overall survival (OS). When comparing OS between 1G and 2G EGFR‐TKIs, propensity score analyses were performed using 2 methods: matching and inverse probability of treatment weighting (IPTW). (Clinical Trial information: UMIN000030121) In total, 1400 patients from 11 institutions were enrolled in this study, and the data from the 1366 patients who received only EGFR‐TKI therapy were analyzed (gefitinib [GEF], N = 732; erlotinib [ERL], N = 416; afatinib, N = 218). Median OS times (months [95%CI]) were 29.7 [27.5‐33.5] in the 1G group (gefitinib, 32.0 [28.1‐35.8]; erlotinib, 27.5 [23.9‐31.7]), and 38.6 [32.2‐NR] in the 2G group (afatinib), respectively. The trend of longer OS for afatinib against 1G EGFR‐TKIs remained, even after adjusted by propensity score. (unadjusted, hazard ratio [HR] 0.676, P = .0023; adjusted by IPTW, HR 0.685 P
Databáze: OpenAIRE
Externí odkaz: